Fluicell

Fluicell Equity Growth

The Year-over-Year Equity Growth of Fluicell (FLUI.ST) as of Nov 20, 2026 is -43.32 %. In the previous year, Year-over-Year Equity Growth was 4,425.65 % — a change of -100.98% (lower).

Equity Growth

-43.32 %

YoY

-100.98%

Last updated:

Year-over-Year Equity Growth of Fluicell is 2025 -43.32 % . Year-over-Year Equity Growth of Fluicell was 2024 4,425.65 % . It decreases by -100.98% lower compared to the previous year.

The Fluicell Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
143.93 SEK
Jan 1, 2019
-56.25 SEK
Jan 1, 2020
90.69 SEK
Jan 1, 2021
-1.98 SEK
Jan 1, 2022
22.68 SEK
Jan 1, 2023
-98.19 SEK
Jan 1, 2024
4,425.65 SEK
Jan 1, 2025
-43.32 SEK
The Fluicell Equity Growth history
YEAREquity GrowthYoY
-43.32 %-100.98%
4,425.65 %-4,607.35%
-98.19 %-532.86%
22.68 %-1,242.84%
-1.98 %-102.19%
90.69 %-261.22%
-56.25 %-139.08%
143.93 %-65.77%
420.48 %+154.41%
165.27 %-497.86%
-41.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Year-over-Year Equity Growth of Fluicell is -43.32 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Fluicell since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Fluicell

All Key Metrics — Fluicell